Your session is about to expire
← Back to Search
ST101 for Advanced Cancer
Study Summary
This trial is testing a new cancer drug to see if it is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2016 Phase 2 trial • 175 Patients • NCT01055314Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have HIV with a CD4+ T-cell count below 350.I have fluid buildup in my abdomen or around my lungs.I do not have any other cancer needing treatment besides the one being studied.I have a long-term condition that causes low platelet counts.You are allergic to ST101 or any of its ingredients.I agree to have two biopsies: one before and one during the study.All my side effects from cancer treatment have improved, except for hair loss.I haven't taken any cancer drugs or undergone certain treatments recently.My tumor cannot be removed by surgery and has spread.I am 18 years old or older.I haven't taken steroids for inflammation or autoimmune issues, or immunosuppressants in the last 30 days.I have an autoimmune disease that needs steroids or immunosuppressants.I have cancer that has spread to my brain or spinal cord.My cancer can be measured by scans and has at least one area that can be tracked over time.I do not have an active hepatitis B or C infection.I am on blood thinners that can't be stopped for a biopsy or had a clotting event recently.My doctor thinks standard treatments won't work for me or I've had bad reactions to cancer treatments.Your heart's electrical activity, as shown on an ECG, takes too long between two specific waves.I am currently on medication for an infection.I am fully active or can carry out light work.My condition worsened or didn't respond to my last treatment.
- Group 1: Dose Expansion CRPC
- Group 2: Dose Expansion Recurrent Glioblastoma
- Group 3: Newly Diagnosed Glioblastoma
- Group 4: Dose Escalation
- Group 5: Dose Expansion HR+ Breast
- Group 6: Dose Expansion Melanoma
- Group 7: Dose Expansion GBM
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants have joined this research endeavor?
"This clinical trial requires 162 participants who possess the specified inclusion criteria. Those interested in joining this medical research can visit Texas Oncology - Baylor Charles A. Sammons Cancer Center in Dallas, Texas and Northwestern Medicine Cancer Centers in Warrenville, Illinois for enrollment."
Does this experiment bring anything new to the scientific community?
"Since 2020, ST101 has been under investigative scrutiny. Sapience Therapeutics sponsored the first study of 162 participants and then followed it up with successful Phase 1 & 2 drug approvals. Currently, there is one active trial for this product ran by Sapience Therapeutics."
Has ST101 been subject to any other scientific investigations?
"The first instance of research on ST101 was conducted in 2020 by the University of Leeds. To date, there are 3 concluded studies and 1 still ongoing clinical trial based mostly out of Dallas, Texas."
What are the projected outcomes of this investigation?
"This 20-month trial's primary objective is to measure Dose-Limiting Toxicity (DLT). Secondary objectives encompass Area Under the Curve (AUC), Duration of Response, and Cmax."
Are there still vacancies available in this research venture?
"Affirmative. The clinical trial is accepting volunteers as per the data available on clinicaltrials.gov. It was originally listed in July of 2020, with updates made up until November 15th 2022; 162 individuals will be recruited from 8 different medical institutions."
How many healthcare facilities are administering this clinical trial?
"Texas Oncology - Baylor Charles A. Sammons Cancer Center in Dallas, Texas, Northwestern Medicine Cancer Centers in Warrenville, Illinois and Columbia University in New york City are amongst the 8 additional medical centres involved with this test."
Share this study with friends
Copy Link
Messenger